MX364314B - Nuevo sulfato de dextrano. - Google Patents
Nuevo sulfato de dextrano.Info
- Publication number
- MX364314B MX364314B MX2017006122A MX2017006122A MX364314B MX 364314 B MX364314 B MX 364314B MX 2017006122 A MX2017006122 A MX 2017006122A MX 2017006122 A MX2017006122 A MX 2017006122A MX 364314 B MX364314 B MX 364314B
- Authority
- MX
- Mexico
- Prior art keywords
- dextran sulfate
- salt
- sulfate
- interval
- average
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 2
- 238000005481 NMR spectroscopy Methods 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000019635 sulfation Effects 0.000 abstract 1
- 238000005670 sulfation reaction Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un sulfato de dextrano, o una sal del mismo, tiene un numero de peso molecular promedio (Mn) según lo medido por espectroscopia de RMN dentro de un intervalo de 1850 y 2000 Da. El sulfato de dextrano, o la sal del mismo, también tiene un número de sulfato promedio por unidad de glucosa dentro de un intervalo de 2.5 y 3.0. Además, una sulfatacion promedio de la posición C2 en las unidades de glucosa del sulfato de dextrano, o la sal del mismo, es de por lo menos 90%. El sulfato de dextrano tiene efectos biológicos mejorados y/o toxicidad reducida en comparación con moléculas de sulfato de dextrano similares disponibles en el mercado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451349A SE538503C2 (en) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
| PCT/SE2015/051188 WO2016076780A1 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017006122A MX2017006122A (es) | 2017-08-10 |
| MX364314B true MX364314B (es) | 2019-04-22 |
Family
ID=55954726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006122A MX364314B (es) | 2014-11-11 | 2015-11-10 | Nuevo sulfato de dextrano. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10407514B2 (es) |
| EP (1) | EP3217988B1 (es) |
| JP (1) | JP6251459B1 (es) |
| KR (1) | KR101834710B1 (es) |
| CN (1) | CN107106595B (es) |
| AU (1) | AU2015347361B2 (es) |
| BR (1) | BR112017009752B1 (es) |
| CA (1) | CA2967264C (es) |
| CY (1) | CY1121336T1 (es) |
| DK (1) | DK3217988T3 (es) |
| EA (1) | EA032383B1 (es) |
| ES (1) | ES2706287T3 (es) |
| HR (1) | HRP20190073T1 (es) |
| HU (1) | HUE042806T2 (es) |
| IL (1) | IL251871A (es) |
| LT (1) | LT3217988T (es) |
| MX (1) | MX364314B (es) |
| MY (1) | MY181598A (es) |
| NZ (1) | NZ731141A (es) |
| PH (1) | PH12017500799A1 (es) |
| PL (1) | PL3217988T3 (es) |
| PT (1) | PT3217988T (es) |
| RS (1) | RS58222B1 (es) |
| SA (1) | SA517381478B1 (es) |
| SE (1) | SE538503C2 (es) |
| SG (1) | SG11201703198PA (es) |
| SI (1) | SI3217988T1 (es) |
| SM (1) | SMT201900032T1 (es) |
| TR (1) | TR201900334T4 (es) |
| WO (1) | WO2016076780A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212708A1 (en) | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| CN110621320B (zh) * | 2017-05-17 | 2023-03-17 | Tx医生公司 | 青光眼的治疗 |
| EP3678675B1 (en) * | 2017-09-08 | 2024-11-20 | TX Medic AB | New use of dextran sulfate |
| EP3810659A1 (en) * | 2018-06-20 | 2021-04-28 | DuPont Industrial Biosciences USA, LLC | Polysaccharide derivatives and compositions comprising same |
| SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| WO2021211043A1 (en) * | 2020-04-15 | 2021-10-21 | Tx Medic Ab | Treatment of coronavirus infections |
| GB202008919D0 (en) | 2020-06-11 | 2020-07-29 | Univ Birmingham | Polysaccharide conpositions and therapeutic gels |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
| CN116322709A (zh) | 2020-10-09 | 2023-06-23 | Tx医生公司 | 使用硫酸葡聚糖的肌肉萎缩的治疗 |
| WO2022220736A1 (en) * | 2021-04-14 | 2022-10-20 | Tx Medic Ab | Treatment of virus infections |
| CN117157084A (zh) * | 2021-10-14 | 2023-12-01 | Tx医生公司 | 病毒感染的治疗 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141014A (en) * | 1960-03-31 | 1964-07-14 | Meito Sangyo Kk | Sodium and potassium salts of the dextran sulphuric acid ester having substantially no anticoagulant activity but having lipolytic activity and the method of preparation thereof |
| JPS4730167Y1 (es) | 1967-03-09 | 1972-09-09 | ||
| JPS469570Y1 (es) | 1968-08-28 | 1971-04-05 | ||
| US4221907A (en) | 1979-07-09 | 1980-09-09 | American Cyanamid Company | Substituted O-α-D and O-β-D-multi-galactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6 α-D-glucopyranoses |
| US4232150A (en) * | 1979-07-09 | 1980-11-04 | American Cyanamid Company | Oligosaccharide precursors to substituted O-α-D and O-β-D-multigalactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6α-D-glucopyranoses |
| US4855416A (en) | 1983-07-25 | 1989-08-08 | Polydex Pharmaceuticals, Ltd | Method for the manufacture of dextran sulfate and salts thereof |
| EP0240098A3 (en) | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
| IL88554A0 (en) | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
| TW318142B (es) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
| JPH08301771A (ja) * | 1995-03-08 | 1996-11-19 | Shiseido Co Ltd | 腎疾患の予防または治療用製剤 |
| AUPN261895A0 (en) * | 1995-04-28 | 1995-05-18 | Australian National University, The | Preparation and use of sulfated oligosaccharides |
| FR2772382B1 (fr) | 1997-12-11 | 2000-03-03 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| JP2000178196A (ja) * | 1998-12-11 | 2000-06-27 | Seikagaku Kogyo Co Ltd | 新規ヒアルロニダーゼ阻害剤及び外用剤 |
| CN1347919A (zh) * | 2000-10-12 | 2002-05-08 | 中国科学院生态环境研究中心 | 带有支链的硫酸酯化寡糖的制备 |
| FR2832708B1 (fr) * | 2001-11-29 | 2004-02-13 | Organes Tissus Regeneration Re | Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires |
| US20040009953A1 (en) * | 2002-01-10 | 2004-01-15 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| SE525461C3 (sv) | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| US20110008343A1 (en) | 2007-06-08 | 2011-01-13 | Lambris John D | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation |
| KR101678429B1 (ko) | 2009-02-02 | 2016-11-22 | 오츠카 세이야쿠 가부시키가이샤 | 저분자량 다황산화 히알루론산 유도체 및 이를 함유하는 의약 |
| SE537742C2 (sv) | 2013-05-13 | 2015-10-13 | Tx Medic Ab | Dextransulfat för cellmobilisering |
| CN103554297B (zh) * | 2013-10-21 | 2016-09-07 | 兰州大学 | 一种高硫代度红芪多糖硫酸酯的制备方法及其应用 |
| US10485817B2 (en) * | 2014-06-12 | 2019-11-26 | Tx Medic Ab | Use of dextran sulfate having an average molecular weight below 10000 DA for inducing angiogenesis in a subject |
-
2014
- 2014-11-11 SE SE1451349A patent/SE538503C2/en not_active IP Right Cessation
-
2015
- 2015-11-10 NZ NZ731141A patent/NZ731141A/en unknown
- 2015-11-10 BR BR112017009752-4A patent/BR112017009752B1/pt active IP Right Grant
- 2015-11-10 SI SI201530562T patent/SI3217988T1/sl unknown
- 2015-11-10 PL PL15858497T patent/PL3217988T3/pl unknown
- 2015-11-10 HR HRP20190073TT patent/HRP20190073T1/hr unknown
- 2015-11-10 TR TR2019/00334T patent/TR201900334T4/tr unknown
- 2015-11-10 CA CA2967264A patent/CA2967264C/en active Active
- 2015-11-10 LT LTEP15858497.9T patent/LT3217988T/lt unknown
- 2015-11-10 KR KR1020177013121A patent/KR101834710B1/ko active Active
- 2015-11-10 DK DK15858497.9T patent/DK3217988T3/en active
- 2015-11-10 SG SG11201703198PA patent/SG11201703198PA/en unknown
- 2015-11-10 ES ES15858497T patent/ES2706287T3/es active Active
- 2015-11-10 MX MX2017006122A patent/MX364314B/es active IP Right Grant
- 2015-11-10 EA EA201790856A patent/EA032383B1/ru not_active IP Right Cessation
- 2015-11-10 JP JP2017525349A patent/JP6251459B1/ja active Active
- 2015-11-10 AU AU2015347361A patent/AU2015347361B2/en active Active
- 2015-11-10 WO PCT/SE2015/051188 patent/WO2016076780A1/en not_active Ceased
- 2015-11-10 HU HUE15858497A patent/HUE042806T2/hu unknown
- 2015-11-10 EP EP15858497.9A patent/EP3217988B1/en active Active
- 2015-11-10 SM SM20190032T patent/SMT201900032T1/it unknown
- 2015-11-10 MY MYPI2017701627A patent/MY181598A/en unknown
- 2015-11-10 RS RS20190040A patent/RS58222B1/sr unknown
- 2015-11-10 US US15/525,818 patent/US10407514B2/en active Active
- 2015-11-10 CN CN201580061059.4A patent/CN107106595B/zh active Active
- 2015-11-10 PT PT15858497T patent/PT3217988T/pt unknown
-
2017
- 2017-04-23 IL IL251871A patent/IL251871A/en active IP Right Grant
- 2017-04-27 PH PH12017500799A patent/PH12017500799A1/en unknown
- 2017-05-07 SA SA517381478A patent/SA517381478B1/ar unknown
-
2019
- 2019-01-10 CY CY20191100024T patent/CY1121336T1/el unknown
- 2019-07-24 US US16/520,930 patent/US10730960B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY181598A (en) | New dextran sulfate | |
| WO2016060996A3 (en) | Interleukin-15 compositions and uses thereof | |
| WO2016086036A3 (en) | Methods and compositions for 18f-radiolabeling of biologics | |
| NZ718962A (en) | Cancer models and associated methods | |
| JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
| MX367853B (es) | Ácido hialurónico entrelazado injertado con dextrán. | |
| WO2015026601A3 (en) | Dithiol mucolytic agents | |
| HK1209031A1 (en) | Polysaccharide compositions and methods of use | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| Cvetković et al. | Graphs with least eigenvalue− 2: ten years on | |
| HK1256902A1 (zh) | 氯犬尿氨酸的前体药物 | |
| AR104435A1 (es) | Procedimiento para producir un producto de té | |
| WO2015123439A3 (en) | Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma | |
| RU2014134634A (ru) | Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола | |
| TH173512A (th) | เดกซ์แทรนซัลเฟตชนิดใหม่ | |
| Chen et al. | On the Road to Conquering Cancer with You: Notes on the New Look of Our Publication | |
| Khutoryanskiy | Showcasing research by Michael T. Cook, Sarah L. Smith and Vitaliy V. Khutoryanskiy from the University of Reading and University of Hertfordshire, UK | |
| EA201700037A1 (ru) | Производные 2н-хромена в качестве анальгезирующих средств | |
| TH155840S (th) | อุปกรณ์ปรับระดับ | |
| TH155839S (th) | อุปกรณ์ปรับระดับ | |
| Fofiu | THE AGEING PHENOMENON | |
| HK1241296A1 (en) | Interleukin-15 compositions and uses thereof | |
| Рыфф et al. | ÂÎÇÌÎÆÍÎÑÒЬ ÈÑÏÎËЬÇÎÂÀÍÈß ÁÈÎÒÅХÍÎËÎÃÈЧÅÑÊÎÃÎ ÌÅÒÎÄÀ ÄËß ÎÏÐÅÄÅËÅÍÈß ÑÎËÅÓÑÒÎЙЧÈÂÎÑÒÈ ÂÈÍÎÃÐÀÄÀ | |
| PL124117U1 (pl) | Wózek do bram samonośnych przesuwnych | |
| TH125371S (th) | หน้าตัดราง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |